Second Clinical Medical College of Shanxi Medical University, TaiYuan, China.
Department of Orthopaedics, Second Hospital of Shanxi Medical University, TaiYuan, China.
FEBS Lett. 2019 May;593(10):1089-1101. doi: 10.1002/1873-3468.13387. Epub 2019 May 8.
miR-134 has been shown to be associated with angiogenesis and the progression of osteosarcoma. This study further assessed the effects of miR-134 expression on osteosarcoma cell migration, invasion, and metastasis in vitro and in a nude mouse xenograft model, exploring the underlying molecular events. Luciferase reporter assays revealed that miR-134 directly targets the 3'-UTRs of MMP1 and MMP3 to reduce their expression in osteosarcoma cells. In conclusion, overexpression of miR-134 suppresses osteosarcoma cell invasion and metastasis through the inhibition of MMP1 and MMP3 expression. We propose miR-134 as an attractive novel therapeutic target for the treatment of osteosarcoma.
miR-134 已被证明与血管生成和骨肉瘤的进展有关。本研究进一步评估了 miR-134 表达对骨肉瘤细胞迁移、侵袭和转移的影响，分别在体外和裸鼠异种移植模型中进行，探讨了潜在的分子事件。荧光素酶报告基因检测显示，miR-134 可直接靶向 MMP1 和 MMP3 的 3'-UTRs，从而降低骨肉瘤细胞中它们的表达。综上所述，miR-134 的过表达通过抑制 MMP1 和 MMP3 的表达来抑制骨肉瘤细胞的侵袭和转移。我们提出 miR-134 是治疗骨肉瘤的一种有吸引力的新的治疗靶点。
